Abstract
This systematic review and meta-analysis (PROSPERO identifier: CRD42024616267) evaluates the safety and efficacy of using immune checkpoint inhibitors (ICIs) as a "bridge" or "downstaging" therapy for patients with hepatocellular carcinoma (HCC) awaiting liver transplantation (LT). By analyzing data from 229 patients across eight studies, the research quantifies the risks of allograft rejection and mortality, concluding that pre-transplant immunotherapy is a feasible clinical strategy when managed with appropriate precautions.
Introduction
Liver transplantation is a definitive curative option for hepatocellular carcinoma, yet many patients face the risk of tumor progression while on the waiting list. To mitigate this, clinicians use "bridging" or "downstaging" therapies. Immune checkpoint inhibitors (ICIs), such as PD-1 and PD-L1 inhibitors, have revolutionized cancer care by activating the immune system against tumors. However, their use before transplantation is controversial; there is a significant concern that "priming" the immune system could lead to catastrophic allograft rejection (AR) once the donor organ is introduced and the patient is placed on immunosuppression.
Methodology
The authors conducted a systematic review and meta-analysis in accordance with PRISMA guidelines. They searched major databases, including PubMed, Embase, Cochrane Library, and Web of Science, for relevant studies published through December 2024.
The final analysis included eight studies (one RCT, two retrospective cohorts, and five case series) totaling 229 patients. Statistical pooling was performed using R software, employing random-effects models for heterogeneous outcomes and common-effects models for stable outcomes. Study quality was ensured using the Joanna Briggs Institute (JBI) critical appraisal tools.
Key Results and Insights
The meta-analysis revealed several critical findings regarding the safety profile of pre-transplant ICIs:
- Allograft Rejection (AR): The pooled incidence of rejection was 19% (95% CI: 12%–30%). While significant, the complete recovery rate was high at 78%, indicating that most rejection episodes are reversible with aggressive immunosuppressive treatment.
- Graft and Patient Survival: Graft loss occurred in only 4% of cases. The overall mortality rate was 8%, with only 2% of deaths directly attributed to rejection.
- Oncological Outcomes: The median recurrence-free survival (RFS) was 17.63 months, and the post-transplant HCC recurrence rate was 24%, suggesting that ICIs effectively control cancer progression during the waiting period.
- Drug Class Nuances: PD-L1 inhibitors were associated with a numerically higher rejection rate (24%) compared to PD-1 inhibitors (18%), though this difference did not reach statistical significance.
Discussion
A primary takeaway from the study is the importance of the "washout" period—the time elapsed between the last dose of immunotherapy and the transplant surgery. A window of 1 to 3 months is generally recommended to allow the drug's immune-stimulating effects to dissipate. The high recovery rate from rejection suggests that with vigilant monitoring and standard treatments (such as steroids or ATG), the immunological risks of prior ICI therapy can be successfully managed.
Conclusion and Future Directions
Pre-transplant ICI therapy appears to be a viable strategy for HCC patients, offering oncological benefits that generally outweigh the manageable risks of allograft rejection. However, the study's limitations—including a small total sample size and the retrospective nature of most included data—highlight the need for large-scale, prospective randomized controlled trials. Future research should focus on establishing standardized washout protocols and identifying biomarkers to predict which patients are at the highest risk for rejection.
Summary updated